Imagine feeling out of breath just walking down a hallway, or struggling to tie your shoes because even basic tasks leave you exhausted. For people living with tricuspid regurgitation (TR)—a condition caused by a leaky heart valve—this is a daily reality. TR impacts more than 1.6 million people in the U.S., and until recently, the only option for relief was risky open-heart surgery. But not anymore.
Enter Abbott’s TriClip™ device—a game-changer for people like Gregory, a Vietnam veteran who can now enjoy his passions of tai chi, golf, and traveling again. The TriClip™ is a first-of-its-kind, FDA-approved minimally invasive treatment that repairs the leaky heart valve without the need for major surgery. Delivered through a vein in the leg, the procedure often requires just a single day in the hospital.
This innovative approach means a new lease on life for countless people who were previously told surgery wasn’t an option. With TriClip™, they can breathe easier—literally—and get back to living the life they love.